Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes

Journal of Lipid Research

Volumn 50, Issue 6, 2009, Pages 1216-1222

  Connelly, Philip W ^a,b   Zinman, Bernard ^c   Maguire, Graham F ^a   Mamakeesick, Mary ^e   Harris, Stewart B ^f   Hegele, Robert A ^g   Retnakaran, Ravi ^c   Hanley, Anthony J G ^c,d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Sandy Lake Health and Diabetes Project   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Aboriginal; Estimated glomerular filtration rate; Genotype; High density lipoprotein; Polymorphism; Renal

Indexed keywords

ALANINE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; CYSTATIN C; GLYCINE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; ARTICLE; CANADA; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DISEASE DURATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

ADULT; ARYLDIALKYLPHOSPHATASE; CANADA; CARDIOVASCULAR DISEASES; CYSTATIN C; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLOMERULAR FILTRATION RATE; HUMANS; INDIANS, NORTH AMERICAN; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; RISK FACTORS;

EID: 67650558669     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P800070-JLR200     Document Type: Article

References (46)

1. Costa, L. G., T. B. Cole, and C. E. Furlong. 2005. Paraoxonase (PON1): from toxicology to cardiovascular medicine. Acta Biomed. 76 (Suppl. 2): 50-57.
2. Gaidukov, L., and D. S. Tawfik. 2007. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. J. Lipid Res. 48: 1637-1646.
3. Mackness, M., and B. Mackness. 2004. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radic. Biol. Med. 37: 1317-1323.
4. James, R. W. 2006. A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin. Chem. Lab. Med. 44: 1052-1059.
5. Bhattacharyya, T., S. J. Nicholls, E. J. Topol, R. Zhang, X. Yang, D. Schmitt, X. Fu, M. Shao, D. M. Brennan, S. G. Ellis, et al. 2008. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 299: 1265-1276.
6. Shih, D. M., Y. R. Xia, X. P. Wang, E. Miller, L. W. Castellani, G. Subbanagounder, H. Cheroutre, K. F. Faull, J. A. Berliner, J. L. Witztum, et al. 2000. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275: 17527-17535.
7. Senti, M., M. Tomas, M. Fito, T. Weinbrenner, M. I. Covas, J. Sala, R. Masia, and J. Marrugat. 2003. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J. Clin. Endocrinol. Metab. 88: 5422-5426.
8. Deakin, S. P., and R. W. James. 2004. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin. Sci. (Lond.). 107: 435-447.
9. Hofer, S. E., B. Bennetts, A. K. Chan, B. Holloway, C. Karschimkus, A. J. Jenkins, M. Silink, and K. C. Donaghue. 2006. Association between PON 1 polymorphisms, PON activity and diabetes complications. J. Diabetes Complications. 20: 322-328.
10. Murata, M., T. Maruyama, Y. Suzuki, T. Saruta, and Y. Ikeda. 2004. Paraoxonase 1 Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus. Diabet. Med. 21: 837-844.
11. Kao, Y., K. C. Donaghue, A. Chan, B. H. Bennetts, J. Knight, and M. Silink. 2002. Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. Diabet. Med. 19: 212-215.
12. Letellier, C., M. R. Durou, A. M. Jouanolle, J. Y. Le Gall, J. Y. Poirier, and A. Ruelland. 2002. Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications. Diabetes Metab. 28: 297-304.
13. Hegele, R. A., P.W. Connelly, S.W. Scherer, A. J. Hanley, S. B. Harris, L. C. Tsui, and B. Zinman. 1997. Paraoxonase-2 G148 variant in an aboriginal Canadian girl with non-insulin-dependent diabetes. Lancet. 350: 785.
14. Hegele, R. A., P. W. Connelly, S. W. Scherer, A. J. Hanley, S. B. Harris, L. C. Tsui, and B. Zinman. 1997. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82: 3373-3377.
15. Calle, R., M. I. McCarthy, P. Banerjee, E. Zeggini, C. A. Cull, K. I. Thorne, S. Wiltshire, S. Terra, D. Meyer, J. Richmond, et al. 2006. Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes: UKPDS 76. Diabetologia. 49: 2892-2899.
16. Ikeda, Y., T. Suehiro, M. Inoue, Y. Nakauchi, T. Morita, K. Arii, H. Ito, Y. Kumon, and K. Hashimoto. 1998. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism. 47: 598-602.
17. Mackness, B., P. N. Durrington, B. Abuashia, A. J. Boulton, and M. I. Mackness. 2000. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin. Sci. (Lond.). 98: 355-363.
18. Nishikawa, T., D. Edelstein, and M. Brownlee. 2000. The missing link: a single unifying mechanism for diabetic complications. Kidney Int. Suppl. 77: S26-S30.
19. Dyck, R. F., and L. Tan. 1994. Rates and outcomes of diabetic end-stage renal disease among registered native people in Saskatchewan. CMAJ. 150: 203-208.
20. Young, T. K., J. M. Kaufert, J. K. McKenzie, A. Hawkins, and J.O'Neil. 1989. Excessive burden of end-state renal disease among Canadian Indians: a national survey. Am. J. Public Health. 79: 756-758.
21. Hanley, A. J., S. B. Harris, M. Mamakeesick, K. Goodwin, E. Fiddler, R. A. Hegele, J. D. Spence, A. A. House, E. Brown, B. Schoales, et al. 2005. Complications of type 2 diabetes among Aboriginal Canadians: prevalence and associated risk factors. Diabetes Care. 28: 2054-2057.
22. Harris, S. B., J. Gittelsohn, A. Hanley, A. Barnie, T. M. Wolever, J. Gao, A. Logan, and B. Zinman. 1997. The prevalence of NIDDM and associated risk factors in native Canadians. Diabetes Care. 20: 185-187.
23. 2003. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can. J. Diabetes 27 (suppl 2): S1-S152.
24. Parsons, M. P., D. J. Newman, R. G. Newall, and C. P. Price. 1999. Validation of a point-of-care assay for the urinary albumin:creatinine ratio. Clin. Chem. 45: 414-417.
25. John, W. G., R. Edwards, and C. P. Price. 1994. Laboratory evaluation of the DCA 2000 clinic HbA1c immunoassay analyser. Ann. Clin. Biochem. 31: 367-370.
26. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron. 16: 31-41.
27. Filler, G., A. Bokenkamp, W. Hofmann, B. T. Le, C. Martinez-Bru, and A. Grubb. 2005. Cystatin C as a marker of GFR-history, indications, and future research. Clin. Biochem. 38: 1-8.
28. Beauvieux, M. C., M. F. Le, C. Lasseur, C. Raffaitin, C. Perlemoine, N. Barthe, P. Chauveau, C. Combe, H. Gin, and V. Rigalleau. 2007. New predictive equations improve monitoring of kidney function in patients with diabetes. Diabetes Care. 30: 1988-1994.
29. Connelly, P. W., G. F. Maguire, C. M. Picardo, J. F. Teiber, and D. Draganov. 2008. Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma. J. Lipid Res. 49: 245-250.
30. Hegele, R. A., J. H. Brunt, and P. W. Connelly. 1995. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler. Thromb. Vasc. Biol. 15: 89-95.
31. Fanella, S., S. B. Harris, T. K. Young, A. J. Hanley, B. Zinman, P. W. Connelly, and R. A. Hegele. 2000. Association between PON1 L/M55 polymorphism and plasma lipoproteins in two Canadian aboriginal populations. Clin. Chem. Lab. Med. 38: 413-420.
32. Levey, A. S., J. Coresh, E. Balk, A. T. Kausz, A. Levin, M. W. Steffes, R. J. Hogg, R. D. Perrone, J. Lau, and G. Eknoyan. 2003. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann. Intern. Med. 139: 137-147.
33. Roos, J. F., J. Doust, S. E. Tett, and C. M. Kirkpatrick. 2007. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children-a meta-analysis. Clin. Biochem. 40: 383-391.
34. Premaratne, E., R. J. MacIsaac, S. Finch, S. Panagiotopoulos, E. Ekinci, and G. Jerums. 2008. Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in type 1 diabetes. Diabetes Care. 31: 971-973.
35. MacIsaac, R. J., C. Tsalamandris, M. C. Thomas, E. Premaratne, S. Panagiotopoulos, T. J. Smith, A. Poon, M. A. Jenkins, S. I. Ratnaike, D. A. Power, et al. 2007. The accuracy of cystatin C and commonly used creatinine-based methods for detecting moderate and mild chronic kidney disease in diabetes. Diabet. Med. 24: 443-448.
36. Feingold, K. R., R. A. Memon, A. H. Moser, and C. Grunfeld. 1998. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis. 139: 307-315.
37. Keller, C. R., M. C. Odden, L. F. Fried, A. B. Newman, S. Angleman, C. A. Green, S. R. Cummings, T. B. Harris, and M. G. Shlipak. 2007. Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Kidney Int. 71: 239-244.
38. Moren, X., S. Deakin, M-L. Liu, M-R. Taskinen, and R. W. James. 2008. HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress. J. Lipid Res. 49: 1246-1253.
39. Gaidukov, L., and D. S. Tawfik. 2005. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with apoA-I. Biochemistry. 44: 11843-11854.
40. O'Brien, T., T. T. Nguyen, B. J. Hallaway, D. Hodge, K. Bailey, and B. A. Kottke. 1996. HDL subparticles and coronary artery disease in NIDDM. Atherosclerosis. 121: 285-291.
41. Peynet, J., P. J. Guillausseau, A. Legrand, J. J. Altman, F. Flourie, P. Chanson, J. Poupon, M. N'Guyen, A. Warnet, J. Lubetzki, et al. 1993. Serum LpAI lipoprotein particles in diabetic patients with and without renal lesions of different grades. Diabete. Metab. 19: 355-360.
42. Ng, D. S., T. Chu, B. Esposito, P. Hui, P. W. Connelly, and P. L. Gross. 2008. Paraoxonase-1 deficiency in mice predisposes to vascular inflammation, oxidative stress, and thrombogenicity in the absence of hyperlipidemia. Cardiovasc. Pathol. 17: 226-232.
43. Hegele, R. A. 1999. Paraoxonase genes and disease. Ann. Med. 31: 217-224.
44. Carlson, C. S., P. J. Heagerty, T. S. Hatsukami, R. J. Richter, J. Ranchalis, J. Lewis, T. J. Bacus, L. A. McKinstry, G. D. Schellenberg, M. Rieder, et al. 2006. TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease. J. Lipid Res. 47: 1014-1024.
45. Dantoine, T. F., J. Debord, J. P. Charmes, L. Merle, P. Marquet, G. Lachatre, and C. Leroux-Robert. 1998. Decrease of serum paraoxonase activity in chronic renal failure. J. Am. Soc. Nephrol. 9: 2082-2088.
46. Ikeda, Y., T. Suehiro, T. Itahara, Y. Inui, H. Chikazawa, M. Inoue, K. Arii, and K. Hashimoto. 2007. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin. Nephrol. 67: 358-365.